Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Gross Profit (2025)

Historic Gross Profit for ImmunityBio (IBRX) over the last 3 years, with Q3 2025 value amounting to $31.9 million.

  • ImmunityBio's Gross Profit rose 42217.49% to $31.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.2 million, marking a year-over-year increase of 102089.47%. This contributed to the annual value of $14.7 million for FY2024, which is 227057.88% up from last year.
  • According to the latest figures from Q3 2025, ImmunityBio's Gross Profit is $31.9 million, which was up 42217.49% from $26.3 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Gross Profit registered a high of $31.9 million during Q3 2025, and its lowest value of $40000.0 during Q1 2024.
  • Its 3-year average for Gross Profit is $9.0 million, with a median of $3.6 million in 2024.
  • Data for ImmunityBio's Gross Profit shows a peak YoY increase of 4104750.0% (in 2025) and a maximum YoY decrease of 42217.49% (in 2025) over the last 5 years.
  • Over the past 3 years, ImmunityBio's Gross Profit (Quarter) stood at $139000.0 in 2023, then soared by 5333.09% to $7.6 million in 2024, then skyrocketed by 322.19% to $31.9 million in 2025.
  • Its last three reported values are $31.9 million in Q3 2025, $26.3 million for Q2 2025, and $16.5 million during Q1 2025.